HHS drops Solomon exclusion, and critics focus on Forest's revenue forecasts
This article was originally published in Scrip
The US Department of Health and Human Services has decided it will not seek to exclude Forest Laboratories' chairman, CEO and president, Howard Solomon, from doing business with government medical reimbursement programmes after all. The HHS's Office of the Inspector General (HHS-OIG) has written to the company saying it has closed the case and anticipates no further action in relation to the matter in question.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.